KUBACZKOVÁ, Veronika, Dávid VRÁBEL, Lenka SEDLAŘÍKOVÁ, Lenka BEŠŠE and Sabina ŠEVČÍKOVÁ. Cell-free DNA — Minimally invasive marker of hematological malignancies. European Journal of Haematology. Hoboken: Wiley, 2017, vol. 99, No 4, p. 291-299. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/ejh.12925.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cell-free DNA — Minimally invasive marker of hematological malignancies
Authors KUBACZKOVÁ, Veronika (203 Czech Republic, belonging to the institution), Dávid VRÁBEL (203 Czech Republic), Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Lenka BEŠŠE (203 Czech Republic) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition European Journal of Haematology, Hoboken, Wiley, 2017, 0902-4441.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.595
RIV identification code RIV/00216224:14110/17:00095664
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/ejh.12925
UT WoS 000411525900001
Keywords in English acute lymphoblastic leukemia; acute myeloid leukemia; multiple myeloma; myelodysplastic syndromes
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 13:36.
Abstract
Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.
Links
NV15-29508A, research and development projectName: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu
PrintDisplayed: 13/5/2024 00:23